Enterprise of Rosatom State Corporation
Print version
Main | About the Company | History


JSC Isotope was founded by Joint Resolution No. 962-447 issued by the Central Committee of the Soviet Communist Party and the USSR Council of Ministers on August 22, 1958, as a national company within Soyuzreaktiv run by the USSR Ministry of Chemical Industry.

JSC Isotope was reorganized into Isotope National Association to become part of the State Atomic Energy Committee of the USSR. Being a national company, it had seven branches located in Moscow, Leningrad, Kiev, Minsk, Sverdlovsk, Tashkent, and Khabarovsk to ensure that the domestic economic demand for isotope products was adequately evaluated and met.

Interatominstrument was created as an international alliance in the area of nuclear instrumentation to become an entity within the Council for Mutual Economic Assistance (CMEA). Isotope National Companyplayed a key role in this international association as it both supplied modern radioisotopic equipment to USSR companies and exported it to other countries.

A specialized chemical agents division located in the city of Staraya Kupavna (Noginsk District, Moscow Region) joined Isotope National Company.

Isotope National Company contributed to a wide range of activities regarding radioisotope devices: developing, manufacturing start-up, and application throughout the USSR.

Isotope National Company supplied instruments and equipment to the Tadjourah Nuclear Research Center in Tadjourah (Libya) which was under construction.

At the time of rapid developments in the nuclear energy sector, Isotope National Company supplied nuclear power plants under construction with spectrometric, radiometric and dosimetric equipment as well as automatic radiation monitoring systems, devices for management and controls of reactor facilities, personal protection equipment.

Isotope National Company took an active part in establishment and development of manufacturing of dosimetric and radiometric equipment as well as arranging distribution to the regions contaminated by the Chernobyl Accident.

By Order of the Ministry for Atomic Energy of the Russian Federation No. 343 (issued on September 18,1992), Isotope National Company, USSR was renamed Isotope National Company, Russia. After the dissolution of the USSR, it began to restore its logistics network whereby medical institutions received radioisotope products.

By Order of the Ministry for Atomic Energy of the Russian Federation No. 654 (issued on October 10,1998), Isotope National Company was renamed Federal Unitary Enterprise Isotope National Company.

Federal State Unitary Enterprise Isotope National Company was created within the Ministry for Atomic Energy of the Russian Federation.

Federal State Unitary Enterprise Isotope National Company was transformed into Joint Stock Company Isotope (JSC Isotope).

By Executive Order of the Government of the Russian Federation (issued on November 2, 2009), Federal Service for Technology and Export Control issued general export licenses for radioactive isotopes and isotope containing devices to JSC Isotope which focused its efforts on mitigating radiological threats across former USSR member-states, in Eastern Europe, Asia, and Africa.
JSC Isotope was awarded a primary contract for disassembling and transporting Radioisotope Thermoelectric Generators (RITEGs).

JSC Isotope started a project of setting up a Molybdenum-99 (Mo-99) radioisotope production at JSC RIAR, Dimitrovgrad. The project was named "Creation of Molybdenum-99 Production Facility" (one of the five key innovation projects announced by the Russian President) and set up by the Board for National Economy Modernization and Technological Development under the supervision of the Russian President.
In the modern nuclear medicine, 80% of all diagnostic procedures are performed with the use of Tc-99m generators. Tc-99m is a decay product of Molybdenum-99. Radionuclide diagnostics allow to detect the most dangerous illnesses at an early stage which means saving thousands of lives every day. Despite the growing demand, the worldwide production of this isotope is decreasing due to a shortage in production facilities. Today, the Russian Federation is capable of meeting demands for this key isotope on both local and foreign markets.

In 2011, JSC Isotope continued implementing the project calledEstablishing Molybdenum-99 Production Facility. Eight test batches of Mo-99 were manufactured by the first production line. In December 2011, installation of the second production line, the one of greater capacity, started.

The Company proceeded with the second stage of the Mo-99 production facility construction. Using the equipment supplied by JSC Isotope, JSC RIAR's employees installed the second production line.

A long-term strategy the Company's development on the domestic and international isotope market for the years of 2014 to2030 was adopted. The entire Mo-99 produced by ROSATOM State Corporation enterprises was fully booked. JSC Isotope announced a launch by ROSATOM of the Russian design Co-60 Sealed Radioactive Sources on the international market. Instead of remaining a raw material supplier, the Company focused on supplying high-value ready-to-use products; the deliveries of compounds labelled with C-14 became astarting step.

The first contracts for Russian design Sealed Radioactive Sources based on Co-60 were signed to supply end consumers, namely large irradiation centers all over the world.. As part of the intergovernmental protocol, deals on the first Mo-99 batches to Brazil were reached.

JSC Isotope is defined as an organization authorized to trade and promote isotope products produced by the Rosatom enterprises, on the foreign markets. A strategy for isotope business development was outlined and approved by ROSATOM.

As an operator of the isotope business of ROSATOM State Atomic Energy Corporation, JSC Isotope initiated a number of projects aimed at developing the productive capacity of ROSATOM. In particular, powered by JSC Isotope, projects were launched to start producing Co-60 at LWGR (Light-Water-cooled Graphite-moderated Reactor) and SFR (sodium fast reactor) as well as Ir-192 and I-125 at "IVV" Pressurized Water Reactor (JSC IRM), etc.

An agreement with Brazil was signed for the supply of isotope medical products to become the largest contract not only for Isotope JSC, but also for Rosatom State Atomic Energy Corporation. It will certainly be recorded in the history of the Russian isotope industry. A new product was launched on the market of iridium-191 disks. Lutetium-177 was introduced on the market in the Middle East. Tremendous work was performed to promote iodine-125.

Isotope JSC increased supplies of Lutetium-177 to Brazil tenfold. Moreover, medical isotope products were exported regularly to the global markets. Also, the first delivery of Cobalt-60 to Switzerland was carried out. A three-year contract was signed with a German company regarding guaranteed supplies of Germanium-72 for 2018-2020. The first batch of Molybdenum-100 medical isotope was shipped to a Canadian company which develops an alternative production technology for Tc-99m.

As compared to 2018, the 2019 year-end revenue from sales of isotope products of ROSATOM Isotopic Complex increased by 15%, including the revenue from isotope export sales (+17% by 2018). Medical radioisotopes and stable isotopes became the growth driver. Specifically, Isotope JSC boosted tenfold and more its export of Lu-177 in the form of a solution. Large deliveries of Ge-76 and Mo-100 were also made to the international scientific research groups. In addition, a record quantity of iridium disks were produced and shipped to the foreign companies and organizations of ROSATOM State Corporation.
Isotope JSC was licensed by ASN (The Nuclear Safety Authority of France) to import Co-60 sources of the Russian design into France, thus making it possible for the Company to expand its geography of sales of sources to sterilization centers.

This year saw the solid sales of medical and industrial products that were organized under the pandemic and remote work conditions, while deliveries of medical products by road were successfully arranged during the period of massive flight cancellations. Isotope JSC became the winning bidder at large tenders regarding supplies of industrial sources to the markets of the Russian Federation and the CIS. For the first time, the Active Pharmaceutical Substance based on Lu-177 was delivered to an Italian clinic in order to confirm the EU GMP quality of the product.